Harlan Laboratories. Contract Research Services
|
|
- Barrie Ward
- 6 years ago
- Views:
Transcription
1 Harlan Laboratories Contract Research Services
2 Table of Contents Overview 2 General Services General Toxicology 3 Reproductive Toxicology in Rats and Rabbits 3 Pathology and Histopathology 4 Genotoxicity and Cell Biology 4 Metabolism 5-6 Environmental Sciences 7 Regulatory Affairs 7 Pharmaceutical Services Special Services for Pharmaceuticals 8 9 Medical Device Services Special Services for Medical Devices 10 Chemical Services Special Services for Chemicals 11 Agrochemicals and Biocides Special Services for Agrochemicals and Biocides 12 Alternative Methods Special Services in Alternative Methods Screening Assays 15 Global Availability and Support
3 Harlan Laboratories Contract Research Services is a leading provider of essential, non-clinical contract research and services to the chemical, pharmaceutical, biotech, medical device and agrochemical industries. Our focus is providing the services you need to optimize the discovery and safety of new medicines and chemicals. Our CRS division has nearly 1,300 employees in 7 countries, but we act locally, understanding the value of close relationships and collaboration with our clients. As important as good customer service and relationships are, it s really all about scientific excellence. Today, research is outsourced more than ever, and researchers need to have confidence in their supplier partners. Stability, reliability, consistency, and quality are all essential. That s what Harlan Laboratories offers with our passion for science and decades of proven expertise, both in research models and services and in contract research services. Our Expertise throughout our European facilities offers a full range of non-clinical services to the Pharmaceutical, Chemical and Agrochemical industries: Toxicology and Pathology Genotoxicology and Cytotoxicity testing Analytical Chemistry Physico-chemical Analysis Bionanalytics, including Pharmaco/Toxicokinetic evaluation Protein Analytics Immunology Animal Metabolism Pharmacodynamic models Screening in early product development Predictive and Mechanistic Toxicology Pharmaceutical Quality Control Ecotoxicology Environmental Fate Plant Metabolism Regulatory Affairs and Consulting Program Management Contract Archiving Quality Assurance 2
4 General Toxicology Harlan Laboratories performs a full range of toxicology studies to support the pharmaceutical, chemical, and agrochemical industries. These studies are performed to fulfil global regulatory guidelines and in accordance with good laboratory practice regulations. We offer: Single dose and repeat dose studies through to 2 year carcinogenicity studies in rodents and chronic studies in non-rodents Rodents, rabbits, dogs, minipigs and primates Transgenic mice including transgenic carcinogenicity studies Routes of administration include oral (manual or semi-automated gavage, capsule and feeding), dermal, intraperitoneal, intravenous (bolus and short infusion manually and by continuous infusion in catheterized rats and dogs), intramuscular, subcutaneous, intratrachaeal, intranasal and inhalation Neurotoxicity In Vivo Micro-CT evaluation especially for bones General Services Reproductive Toxicology in Rats and Rabbits Our experienced toxicologists, fetal pathologist and technical staff have extensive expertise and offer a complete range of developmental and reproductive toxicology studies, including: Fertility Embryo-fetal development Pre and postnatal development Maternal Function Routes of administration include oral, dermal, intraperitoneal, intravenous (bolus and infusion), intramuscular, subcutaneous and infusion, intrachaeal and inhalation. 3
5 Pathology and Histopathology The Pathology department is highly experienced in the performance of all general study types including cancer studies and neurotoxicity, medical devices and exotic animals. It s our goal to always finish your studies on time and to your complete satisfaction. Necropsy of all general animal species routinely used in regulatory toxicology General Services Routine tissue trimming, embedding, cutting and staining including Special stains Special techniques - Cryomicrotome - Plastic embedding and ultrathin sections - Diamond saw and grinding Automated immunostaining In situ hybridization Fish and snail pathology Microscopy - Stereomicroscopy - Fluorescence - Image analysis Genotoxicity and Cell Biology Our study directors are recognized experts in the fields of cell biology, genetic toxicology and biocompatibility. They are members of both national and international scientific working groups and are actively engaged in research projects sponsored by the national and EU authorities. As such, our clients benefit from advice based on the latest scientific and regulatory thinking. Their expertise in the areas of immunology, molecular biology and in vitro metabolism is also available to our clients. Our services include: Ames, HPRT, mouse lymphoma test Chromosome Abberation test in vitro and in vivo, both bone marrow and mouse spermatogonia Photomutagenicity Micronucleus test in vitro and in vivo UDS assay in vitro and in vivo COMET assay in vitro and in vivo DNA binding/adducts 4
6 Metabolism Harlan Laboratories supports our clients with ADME studies and programs in all phases of the discovery and development pipeline. These include Lead Optimization programs by in vitro and in vivo PK screening as well as PK or toxicokinetic profiling, mass balance and distribution studies for development projects. Metabolite profiling and identification provides a rationale for the selection of animal species in toxicology studies. Harlan also provides solutions for occupational and consumer studies of chemicals, agrochemical products and veterinary pharmaceuticals. General Services 14 C, 3 H and 125 I radiolabelled materials All relevant species All routes of administration CYP interaction, inhibition, induction Metabolic stability with liver S9 preparation Phase II reactions such as conjugation Protein binding Dermal penetration HPLC, GC, CE, TLC LC-MS/MS and GC-MS QWBA Real time QPCR ICP-MS Analytics and Bioanalytics The analytical departments of Harlan Laboratories feature state of the art instrumentation and methodology. Techniques routinely available for new chemical entities include HPLC, HPLC-MS/MS, High-Resolution-MS, GC, GC-MS, GPC, UV/Vis, FTIR, AAS, NMR. For biologicals ELISA, RIA, electrophoresis, capillary electrophoresis, real-time QPCR and in vivo bioassays are routinely available. 5
7 General Services Analytical data and results will be provided to support toxicological and ecotoxicological studies such as: Development of analytical methods and method validation Analysis of dose preparations for toxicity studies Bioanalysis in plasma, urine and tissues Biochemical analysis of biologics In vivo bioassays In addition, we have extensive experience and expertise in the testing of physico-chemical properties for agrochemical and chemical notifications and can offer the complete package of physico-chemical tests required for REACH. Services include: Physico-chemical properties Hazardous properties Pharmacopoeial and other physicochemical testing Quality control of drugs and API under GMP Establishment of specification for API drug development Stability testing (according to ICH guideline) Product characterization Identification and characterization of active ingredients and formulations Testing of containers and packaging materials Certification of reference material Polymer Analysis Migration studies and modeling Extraction studies Identification of unknown contaminants, metabolites and degradation products Workplace exposure monitoring Residue analysis 5-batch analysis Storage stability to EU/OPPTS US EPA guidelines Client-defined, custom-designed analytical studies 6
8 Environmental Sciences Harlan Laboratories offers extensive expertise in the conduct of aquatic and terrestrial ecotoxicological studies on industrial chemicals, agrochemicals, biocides, and more recently on veterinary medicines and pharmaceutical products. The studies are performed according to the international test guidelines of OECD, EU, EPA/OPPTS, ISO and JMAFF. For a refined risk assessment, higher-tier studies under more realistic environmental conditions are available, such as studies in water sediment systems in laboratories or outdoor mesocosm pond studies. Our ecotoxicity team has extensive expertise in the evaluation of difficult substances with challenging physio-chemical properties (e.g. low water solubility, instability, volatility, strong adsorption or colouration). The ecotoxicology team is supported by the modern analytical laboratories of Harlan Laboratories which offer analytical techniques suitable for use in all biophysical matrices encountered in ecotoxicological studies. Services include: Acute and chronic Daphnia toxicity Algal growth test Acute and chronic toxicity in fish Fish early-life-stage tests Fish bioaccumulation Earthworm toxicity Activated sludge respiration inhibition Ready and inherent biodegradation Hydrolysis tests Adsorption/desorption screening and full studies Soil sediment simulation tests Effects on soil microorganisms Effect on non-target arthropods including honeybees Soil litterbag studies Short term plant toxicity Field Trials and plant metabolism Environmental fate and modeling Avian studies Mesocosm studies General Services Regulatory Affairs Our regulatory affairs managers and risk assessment experts provide seamless development and execution of regulatory strategies. We maintain close contact with major authorities and thus remain on top of the latest developments in regulatory requirements. Our vast experience and in-depth knowledge ensures that your projects are managed by true experts who enable you to bring your product to market in a rapid and cost-effective manner. Further details on our regulatory affairs services are presented in the industry specific special services sections. 7
9 Special Services for Pharmaceuticals The first administration of a new investigational medicinal product in human beings is a very important step in the development of a new drug. The transition from non-clinical to early clinical development marks a milestone in the destiny of the compound. Pharmaceutical Services Based on our extensive and globally recognized expertise, the multidisciplinary team of specialists in Harlan Laboratories provides a truly integrated service for new chemical entities, biologicals and phytopharmaceuticals from strategic development planning, through project performance, up to dossier preparation for clinical trial authorization or product registration. Pharmacokinetics (PK) and Bioanalytics The early screening of several lead substances to select candidates for a pre-clinical test program is one of the most critical points in the drug development. Harlan Laboratories has established a range of rapid and cost effective of techniques to make drug discovery more successful. Single and multiple administration via oral, dermal, intraperitoneal, intravenous (bolus and infusion), intramuscular, subcutaneous and infusion, intrachaeal, intranasal and inhalation. Rodent, Rabbit, Dog, Minipig and Primate Automated blood sampling Bioanalytics including LC-MS/MS, High-Resolution-MS, GC-MS, RIA, Elisa, CE and RT-PCR Bioanalytics and toxicokinetics (TK) in toxicity studies PK evaluation using WinNonLin or PK Solutions Pharmacodynamic and efficacy models for central and peripheral nervous system, cardiovascular and respiratory system, gastrointestinal and renal system and specialized efficacy studies Safety Pharmacology Safety pharmacology studies contribute to the risk assessment of NCEs in pharmaceutical development by identifying undesirable pharmacodynamic properties before the first administration to man (Phase I). These studies can also be used to evaluate adverse effects observed in toxicology or early clinical trials and to investigate the mechanism(s) underlying them. Safety pharmacology studies should be performed in accordance with the ICH S7A and S7B guidelines and to GLP. Harlan Laboratories has over 14 years of experience in performing safety pharmacology studies in compliance with GLP and our services include: Central Nervous System - Modified Irwin Screen - Functional Observation Battery Cardiovascular system - Telemetered animals - Anaesthetized animals - In vitro HERG-1 assay - Guinea Pig papillary muscle Wide range of disease models 8
10 Special development programs Our experienced program managers offer specialized, tailor made programs of toxicological studies fulfilling all requirements which are necessary for taking a new active pharmaceutical ingredient first time in man. These Fast-intoman study packages benefit from comprehensive program management in very close cooperation with the client and provide a time- and cost-effective way to initiate clinical phase I studies. Regulatory Affairs Our regulatory affairs managers and risk assessment experts work together to provide seamless development and execution of regulatory strategies. We stay in close contact with major authorities and thus remain on top of the latest developments in regulatory requirements Advice on regulatory requirements and testing strategies Negotiation with authorities Preparation of registration dossiers Compilation of dossiers including CTD Follow up on submissions Dealing with deficiency lists and variations Preparation of drug master files Applications for certificates of suitability Expert opinions, reviews Pharmaceutical Services 9
11 Medical Device Services Special Services for Medical Devices Harlan Laboratories knows the special regulations for the assessment of efficacy and safety for medical devises. Our deep expertise can assist with the regulatory requirements, testing and reporting required for approval. Our Services include: In vitro assessment of cytotoxicity and genotoxicity In vitro and in vivo assessment of efficacy / feasibility of intended application In vivo safety assessment according to standard guideline procedures Toxicological profiling of materials for Medical Devices Material characterization by biological and toxicological evaluation with acute, subacute, subchronic and chronic toxicological studies. Biocompatibility testing of Medical Devices according to ISO Strategic planning of study program Genotoxicity, carcinogenicity, reproductive toxicity Hemocompatiblity, static and dynamic systems Cytotoxicity Implantation, e.g. vascular stents Vascular grafts, bioresorbable polymers, histopathology Osseous implantation (rabbit and sheep) with CT-/MRI-monitoring Intracranial implantation Determination of ethylene oxide sterilization residuals Determination of material degradation, irritation and sensitization 10
12 Special Services for Chemicals REACH offers the opportunity to reduce costs, perform the appropriate testing according to regulations, and provides guidance on producing quality Technical Dossiers and Chemical Safety Reports. Harlan Laboratories has vast experience in the worldwide regulatory process for substances and our experts assess data requirements, ensure that the correct tests are performed, and achieve acceptance in the regulatory community. Services include: Strategic planning of test programs and registration strategies Project Management and study monitoring of test programs in toxicology, analytics and ecotoxicology Data analysis and interpretation Data compensation appraisals Liaison with regulatory authorities and scientific bodies Expert reports Risk assessments Product safety evaluations Dossier compilation and submission Literature searches/inventory checks Product defense Regulatory compliance check and certification Chemical Services Task force and consortia management REACH Services Client representation and consortia management SIEF negotiations Portfolio examination Development of intelligent testing strategies Preparation of Technical dossiers and chemical safety assessments Seminars and training 11
13 Special Services for Agrochemicals and Biocides Agrochemicals and Biocides Our vast experience and in-depth knowledge ensures that your projects are managed by experts who help bring your product to market quickly and cost-effectively. Services include: Test programs Strategic planning of intelligent test programs Project Management and study monitoring of test programs Data analysis and interpretation Design and protocol development of higher-tier studies Residue studies Development and Registration Regulatory compliance review Dossier preparation (OECD/BPD) and submission Electronic submissions (CADDY, IUCLID, R4BP) Regulatory Support Data compensation appraisals Liaison with regulatory authorities and scientific bodies Expert reports Literature searches/inventory checks Risk assessment across all scientific disciplines Regulatory strategies Liaison with regulatory agencies Product defense Product safety evaluations Issue management Partnership Task force management and technical advice, client representation Management of global registrations Management of development programs Global logistics Seminars and training 12
14 Special Services in Alternative Methods Harlan is committed to the principle of the 3R s of Replacement, Reduction and Refinement and few companies can match our range of services and depth of experience in non-animal alternative methods. Harlan is pro-active in the development and use of in vitro and ex vivo methods. We partner with researchers and clients in pre-validation and formal validation studies to achieve your testing needs. Alternative Methods Immunology Lymphocyte blastogenesis Analysis of natural killer cell activity Analysis of macrophage function Reproductive Toxicology Embryonic mouse stem cell test Toxicity Assessment of starting dose for acute systemic toxicity using neutral red uptake Target organ toxicity with primary cells and cell lines from various organs Balb/3T3 neutral red uptake for phototoxicity evaluation Eye Irritancy Bovine corneal opacity and permeability test (BCOP) Hens egg chorionallantoic membrane test (HET-CAM) Reconstructed human corneal epithelial models (e.g. EpiOcular) Rabbit and chicken enucleated eye tests (REET and CEET) Skin Corrosivity Reconstructed human skin equivalents for assessment of skin corrosivity (OECD 431) Transcutaneous electrical resistance assay (TER; OECD 430) Corrositex membrane barrier test (OECD 435) 13
15 Skin Irritancy Reconstructed human skin equivalents for assessment of skin irritancy (EU B 46) Barrier Systems Dermal Penetration using flow-through diffusion cells and human and pig isolated skin systems Intestinal uptake using CaC0-2 absorption models Blood brain barrier systems using pig brain microvascular endothelial cells Alternative Methods In vitro metabolism Interspecies comparative metabolism Selective human cytochrome P450 metabolism Human cytochrome P450 inhibition MDR (P-glycoprotein) interaction assays Carcinogenicity Cell transformation assays for detecting initiators and promotors: Balb/c3T3 assay and Syrian hamster embryo (SHE) cell assayselective In silico Safety Modelling Structure activity relationship by computerized models (TOPKAT and DERE) 14
16 Screening Assays Harlan Laboratories knows assay development, early screening and drug development. Compounds at early research stages are screened to gain data on safety and efficacy. Tests include in vitro screening of adsorption, distribution, metabolism, excretion, and toxicity and genotoxicity. Alternative Methods Comet assay DNA binding/adducts Screening Ames, micronucleus, mouse lymphoma and Comet assays Cell-based assays Phototoxicity Cytotoxicity Cell line characterization Cell transformation assay (SHE, Balb/c 3T3) Biochemical analysis Virus safety Prion Safety Other endpoints PK screen with automated blood sampling QT prolongation (HERG)/other ion channels Oxidative stress Endocrine toxicology Enzymology 15
17 Global availability and support At Harlan Laboratories, we have a passion for science and for developing solutions to help you achieve your goals. With contract research services, research models, and laboratory animal diets, we can support your global research needs. Contract Research Services Our locations in 7 countries across Europe and Asia can assist with non clinical research needs for the pharmaceutical, biotech, medical device, chemical, and agrochemical industries. Research Models and Services Harlan Laboratories is committed to the welfare and quality of our animal models. Our veterinary, scientific and quality staffs are committed to ensuring our company mission helping you do research better. Our global line of research models includes mice, rats, rabbits, dogs and primates. Teklad Global Diets Harlan Laboratories Teklad Diets have grown to be an industry leader by concentrating on reducing research variables through quality and consistency. Our nutritionists provide support and technical advice to help with your diet selection. Our diets are available world-wide. 16
18 Find out more We re Harlan Laboratories. And we re here to help you do research better. Contact your sales representative or visit us on the Web at Corporate Headquarters Harlan Laboratories, Inc Allison Pointe Blvd., Suite 400 Indianapolis, IN Harlan, Harlan Laboratories, the Harlan logo and Teklad Global Diets are trademarks of Harlan Laboratories, Inc Harlan Laboratories, Inc.
THE ANSWERS YOU NEED ARE ALL RIGHT HERE
Battelle Toxicology THE ANSWERS YOU NEED ARE ALL RIGHT HERE Pre-Clinical Toxicology Industrial Toxicology Environmental Exposure Studies PUT THE POWER OF BATTELLE TO WORK FOR YOU Whether you re trying
More informationIn Vitro Testing in Contract Research: A Valid Alternative? Robert Guest Head of Alternative and Acute Toxicology
In Vitro Testing in Contract Research: A Valid Alternative? Robert Guest Head of Alternative and Acute Toxicology Primary Objectives Presentation Outline Contract Research Organisations Setting the Scene
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationPublic Interest Incorporated Foundation BioSafety Research Center
Public Interest Incorporated Foundation BioSafety Research Center http://www.anpyo.or.jp Ver. 201801 Building #1(Test and research annex) Building #2 (Administrat ion office) Building #3 (Toxicity test
More informationEnvigo Corporate & Industry Overview. Rutgers University
Envigo Corporate & Industry Overview Rutgers University Joseph Bedford, Ph.D. Corporate Vice President, Strategic Marketing November 15, 2016 envigo.com 1 Who we are Envigo is a global contract research
More informationA Global CRO STRONGER TOGETHER
A Global CRO STRONGER TOGETHER About us Unique Service Offering the first agrochemical CRO to offer a truly global service Part of the Eurofins Scientific Group of companies, Eurofins Agroscience Services
More informationOur Business. in vitro / in vivo. in vitro / in vivo ADME. in vitro / in vivo. Toxicology. Cell Battery V79. Analytical Services. Service.
GenPharmTox is one of the few CROs who can guarantee the success of our project within the given time framework and on the terms agreed. Dr. Michael Runkel, Apogepha GmbH 3 3 In vitro 3.1. Phototoxicity
More informationPreclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment
Preclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment Hubert Dirven Lead Validation Unit - NPI Amersham Health (GE Healthcare), Oslo Preclinical
More informationPRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016
PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 1 FROM DISCOVERY TO COMMERCIALIZATION At least 10 years on average Average spend of $1.4B Less than 12% of drugs entering Phase I are approved
More informationGuide to Services Our service map.
Guide to Services Our service map www.citoxlab.com France Full service nonclinical drug development LEADSCREEN TM : accelerated predictive toxicology screening Genetic toxicology Biomarkers and immunology
More informationOptimisation de votre programme de développement
Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500
More informationSAFETY RESEARCH INSTITUTE FOR CHEMICAL COMPOUNDS CO., LTD.
SAFETY RESEARCH INSTITUTE FOR CHEMICAL COMPOUNDS CO., LTD. HISTORICAL BACKGROUND I. PREDECESSOR CONCERN (SAFETY STUDY ASSOCIATION) The origin of our company is a group of researchers, Safety Study Association,
More informationThe TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices
A leading Australian contract research organisation (CRO) providing integrated preclinical drug development services to the biotech and pharmaceutical industries The TetraQ Difference Located at The University
More informationData Requirements for New Chemical Notification in China Please go to for more info about China REACH
Data Requirements for New Chemical Notification in China Please go to http://www.cirs-reach.com/ for more info about China REACH Original Article by Chemical Inspection and Regulation Service (CIRS) in
More informationTesting Methods and Directives
EUROPEAN COMMISSION DIRECTORATE GENERAL - JRC JOINT RESEARCH CENTRE Institute for Health and Consumer Protection Unit: Toxicology and Chemical Substances European Chemicals Bureau D:\My Documents\JR\Tables\OFFJOUR\Listofoj.doc
More informationACVM - REGISTRATION STANDARD FOR TOXICOLOGY AND ENVIRONMENTAL TOXICOLOGY
ACVMS 9.1 Ministry of Agriculture and Forestry Post Office Box 2526 WELLINGTON, NEW ZEALAND ACVM - REGISTRATION STANDARD FOR TOXICOLOGY AND ENVIRONMENTAL TOXICOLOGY This document may be altered at any
More informationParacelsus Course Objectives: Toxicology for the Laboratory Animal Scientist. General Toxicology Investigations. Reproductive Toxicology
Toxicology for the Laboratory Animal Scientist CL Davis Foundation Topics in Laboratory Animal Medicine May 7, 2009 Angela King-Herbert, DVM, DACLAM NTP/NIEHS RTP NC Course Objectives: Define terms used
More informationMedical Device Testing. Andrew Makin, MSc, ERT, MRSB Scientific Director CiToxLAB Scantox, Denmark
Medical Device Testing Andrew Makin, MSc, ERT, MRSB Scientific Director CiToxLAB Scantox, Denmark Medical device Risk evaluation Efficacy Biocompatibility Clinical testing Pharmaceutical product Preclinical
More informationBasic principles of the safety assessment of drugs
Basic principles of the safety assessment of drugs SFT Annual meeting 2013 Björn Dahl, PhD Senior Project Director Global Safety Assessment AstraZeneca R&D Outline of presentation Safety assessment in
More informationMB Expands Capabilities Adds Ames Test, MTD and Range Finding
What's New @ MB? MB Expands Capabilities - Ames, PK, MTD, Range Finding New! - PorCORA - Non-Animal Ocular Irritation/Reversibility Test Under Development - PorFocal - Low-Level Ocular Irritation Screening
More informationGuidance Documents for New Chemical Substance Notification in China (China REACH) Non Official
Guidance Documents for New Chemical Substance Notification in China (China REACH) Non Official On 19 Jan 2010, the Ministry of Environmental Protection (MEP) of China released the revised version (MEP
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationGuidance for Industry
Guidance for Industry M4S: The CTD Safety U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research
More informationAn NGO Perspective on Regulatory Acceptance of Non-animal Data and Related Issues. Martin Stephens, Ph.D. The Humane Society of the United States
An NGO Perspective on Regulatory Acceptance of Non-animal Data and Related Issues Martin Stephens, Ph.D. The Humane Society of the United States Animal Use Numbers Rabbits 222,167 Guinea pigs 203,098 Hamsters
More informationYour bridge to. better medicines
Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)
More informationDISCOVER OUR SEGMENT REGULATORY SCIENCE
DISCOVER OUR SEGMENT REGULATORY SCIENCE Our focus In the demanding regulatory environment of the EU, expert knowledge is essential to gaining approval for substances and products. That is why the scientific
More informationCosmetics Europe LRSS Programme
Cosmetics Europe LRSS Programme 2016-20 Rob Taalman Objectives of CE Research To deliver tools & strategies for animal-free safety assessment Accurate Robust Efficient ultimately accepted by regulators
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationGuide to Services Our service map
Guide to Services Our service map www.citoxlab.com France Full service nonclinical drug development LEADSCREEN TM : accelerated predictive toxicology screening Genetic toxicology Biomarkers and immunology
More informationComments and suggestions from reviewer
Comments and suggestions from reviewer Page 1 of 13 Title: WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology: WHO/rDNA_DRAFT/12
More informationOncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges
The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory
More informationGUJARAT UNIVERSITY POST GRADUATE DIPLOMA IN TOXICOLOGICAL SCIENCES EFFECTIVE FROM JUNE 2018
GUJARAT UNIVERSITY POST GRADUATE DIPLOMA IN TOXICOLOGICAL SCIENCES EFFECTIVE FROM JUNE 2018 DEPARTMENT OF ZOOLOGY, BIOMEDICAL TECHNOLOGY AND HUMAN GENETICS UNIVERSITY SCHOOL OF SCIENCES GUJARAT UNIVERSITY
More informationAccelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective
Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA
More informationCYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE DMPK OVERVIEW XENOGRAFT MODELS ADME SUMMARY REPORT.
CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE XENOGRAFT MODELS DMPK OVERVIEW ADME SUMMARY REPORT DMPK Overview QPS provides immediate access to a dedicated team of experienced
More informationGLOBAL CHEMICAL REGISTRATIONS: TESTING STRATEGIES AND CMO COMMUNICATION
GLOBAL CHEMICAL REGISTRATIONS: TESTING STRATEGIES AND CMO COMMUNICATION HPAPI Summit June 21, 2017 Jessica Graham, Ph.D., DABT Senior Research Investigator, Product Quality and Occupational Toxicology
More informationFrom Drug Discovery to IND Saving Time and Money Through Smart Study Design
From Drug Discovery to IND Saving Time and Money Through Smart Study Design Stephen Madden BSc PhD CBiol FSB Head, Metabolism and Pharmacokinetics Charles River Preclinical Services, Edinburgh Outline
More informationBioanalytical Support to In Vitro Studies
Bioanalytical Support to In Vitro Studies Presenter: Tim Sangster (on behalf of EBF (mini-workshop)) Open Symposium 2017 November 17 th 2017 Barcelona http://www.europeanbioanalysisforum.eu Agenda Ø Scope
More informationTOXICITY STUDIES. Mr.D.Raju M.Pharm., Lecturer
TOXICITY STUDIES Mr.D.Raju M.Pharm., Lecturer INTRODUCTION A drug is a single substance or mixture of substances used for diagnosis, treatment, mitigation or prevention of disease ; restoring, correcting
More informationEFSA Guidance on the Submission of a. Evaluation: Toxicological data
Committed since 2002 to ensuring that Europe s food is safe EFSA Guidance on the Submission of a Dossier on Food Enzymes for Safety Evaluation: Toxicological data Prof. Karl-Heinz Engel CEF Panel member
More informationIs your next regulatory deadline within REACH?
Is your next regulatory deadline within REAC? 2018 500ml Smithers Viscient testing schedule REAC Annex VII/VIII Guideline Study Type Week Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
More informationSupplementary exam work (Number, form, scope) Courses (type of teaching) Contact time. Winter semester
IEW-M1.1 Principles in Toxicology Number of credit points (CP): 12 Introduction to general toxicology Foundations of toxicokinetics (ADME: absorption, distribution, metabolism, and excretion) Foundations
More informationFirst-in-human clinical trials Behind the scenes
First-in-human clinical trials Behind the scenes Dr Douglas Francis BVSc MVSc PhD, UK/European registered toxicologist Principal Regulatory Toxicologist Prior to review by Bellberry Ethics Committee Identify
More informationFrom Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager
From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,
More informationNON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS. Cutting-Edge Science and Constant Innovation: The Keys to Success
NON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS Cutting-Edge Science and Constant Innovation: The Keys to Success 2 NON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS Cutting-Edge
More informationKey Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety
Safeguarding public health Key Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety David R Jones (david.jones@mhra.gsi.gov.uk) Expert Pharmacotoxicologist, Medicines and
More informationSubstances characterization & (eco)toxicity
Substances characterization & (eco)toxicity (according to REACH, CLP, BPR, CPR, PPP) Mérieux NutriSciences group offers a complete package of analytical services suitable for the identification and (eco)toxicological
More information- A6/18 - Format for the listing of test and study reports and other documentation PART 4
- A6/18 - PART 4 OECD, EU, US, CANADIAN, JAPANESE AND AUSTRALIAN NUMBERING SYSTEMS FOR DATA AND INFORMATION ON PHEROMONE AND OTHER SEMIOCHEMICAL ACTIVE SUBSTANCES 1. As indicated in subparagraph 3.1.1
More informationSPEED UP YOUR TIME TO MARKET
SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies
More informationApproval process for veterinary medicinal products in Japan
The JVPA forum 2016 Harumi, Tokyo, December 21, 2016 Approval process for veterinary medicinal products in Japan Evaluation and Organization Section, Planning and Coordination Division National Veterinary
More informationMOVE YOUR DRUG FROM CONCEPT TO IND WITH CONFIDENCE
www.advinus.com MOVE YOUR DRUG FROM CONCEPT TO IND WITH CONFIDENCE CLINCIAL CANDIDATE IDENTIFICATION LEAD OPTIMISATION PROCESS CHEMISTRY INTEGRATED PRECLINICAL DEVELOPMENT SERVICES ANALYTICAL R & D SAFETY
More informationAPPENDIX IV OECD GUIDELINES FOR TESTING OF CHEMICALS. 1- The OECD Test Guidelines submission and adoption process
APPENDIX IV OECD GUIDELINES FOR TESTING OF CHEMICALS 1- The OECD Test Guidelines submission and adoption process The OECD Test Guidelines Programme provides the mechanism for developing new Test Guidelines,
More informationNUVISAN GROUP. Our Philosophy
NUVISAN GROUP Our Philosophy 2 EARLY DEVELOPMENT Introduction to Nuvisan Fully integrated Contract Research Organisation headquarted in Neu-Ulm, southern part of Germany. Nuvisan - Early Development Headquartered
More informationSupplementary exam work (Number, form, scope) Courses (type of teaching) Contact time. Winter semester
READING VERSION OF MODULE DESCRIPTIONS The module descriptions are not part of the Regulations; they are integrated into the First Amendment to the Module Catalog. IEW-M1.1 Principles in Toxicology Number
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL TRIALS WITH A SINGLE MICRODOSE
European Medicines Agency Evaluation of Medicines for Human Use London, 23 June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL
More informationThe Role of Chemistry in Adverse Outcome Pathways. Paul Russell & Steve Gutsell Safety and Environmental Assurance Centre, Unilever April 2013
The Role of Chemistry in Adverse Outcome Pathways Paul Russell & Steve Gutsell Safety and Environmental Assurance Centre, Unilever April 2013 Contents Background Risk Assessment in FMCG industry Drivers
More informationMedical Devices INNOVATIVE SOLUTION FOR THE HEALTHCARE
Medical Devices INNOVATIVE SOLUTION FOR THE HEALTHCARE Medical Devices The new Regulation 745/2017 defined as Medical Device any instrument, apparatus, appliance, software, implant, reagent, material or
More informationAnimal Use in the Safety Evaluation of Chemicals: Harmonization and Emerging Needs
Animal Use in the Safety Evaluation of Chemicals: Harmonization and Emerging Needs Horst Spielmann Abstract An overview is provided of the legal framework in Europe for the use of experimental animals
More informationRevidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung. Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität
Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität PD Dr. Elke Röhrdanz Präklinik Fachgebiet Klinische Prüfung
More informationCHEMICAL SAFETY REPORT. Substance Name: Glucose EC Number: CAS Number: Registrant's Identity: Example Company 1
CHEMICAL SAFETY REPORT Substance Name: Glucose EC Number: 200-075-1 CAS Number: 50-99-7 Registrant's Identity: Example Company 1 Table of Contents Part A... 1 1. SUMMARY OF RISK MANAGEMENT MEASURES...
More informationSTUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO TESTING
VICH GL33 (SAFETY: GENERAL APPROACH) October 2002 For implementation at Step 7 - Final STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO TESTING Recommended
More informationCooperation in the field of toxicology, analytics, R&D and production
Cooperation in the field of toxicology, analytics, R&D and production Where you can find us 2 2 VUOS PARTNER FOR COOPERATION History 3 3 VUOS PARTNER FOR COOPERATION Organizational structure 1. R&D and
More informationDMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION
CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE XENOGRAFT MODELS DMPK OVERVIEW ADME SUMMARY REPORT DMPK Overview QPS is your Global Link to all your DMPK Sourcing Needs Introduction
More informationDetection of toxicity to reproduction for human pharmaceuticals. Explanatory slides agreed by EWG members
Detection of toxicity to reproduction for human pharmaceuticals Explanatory slides agreed by EWG members 2 October 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals
More informationMAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS FOR PHARMACEUTICALS M3(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE MAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL
More informationJuvenile toxicity studies with biopharmaceuticals : considerations and current practices
Juvenile toxicity studies with biopharmaceuticals : considerations and current practices Shaun Maguire Toxicologist, Biologics Safety Assessment, MedImmune, Cambridge, UK maguires@medimmune.com AGAH Workshop
More informationOUR MISSION OUR EXPERTISE OUR SERVICES
Capacités Biotherapeutics Solutions (C.B.S) is a newly created business unit of CAPACITÉS LLC, an affiliate company of the University of Nantes (France). By gathering experts and core facilities, C.B.S
More informationWhat can be done from regulatory side?
Federal Agency for Medicines and Health Products (FAMHP) What can be done from regulatory side? 9th Annual ecopa Workshop November 29-30, 2008, Brussels Dr. Sonja BEKEN Non-Clinical Assessor, Registration
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationDRUG REGISTRATION REGULATION
DRUG REGISTRATION REGULATION Registration Categories and Application Information Requirements of Chemical Drugs I Registration Categories 1) New chemical entity never marketed in any country. i. Drug substance
More informationAn ASEAN guidance document for evaluating the safety of botanical. [Version ] Botanical Safety Assessment.
ASEAN Cosmetic Scientific Body Botanical Safety Assessment Guidance Document [Version 2014-01] An ASEAN guidance document for evaluating the safety of botanical An ASEAN Guidance document for evaluating
More informationAMERICAN CHEMISTRY COUNCIL LONG-RANGE RESEARCH INITIATIVE REQUEST FOR PROPOSALS
AMERICAN CHEMISTRY COUNCIL LONG-RANGE RESEARCH INITIATIVE REQUEST FOR PROPOSALS RfP Title Physiological Parameters and Physiologically Based Pharmacokinetic Modeling for the Perinatal Period RfP Number
More informationDermal Studies at CBI
Dermal Studies at CBI Comparative Biosciences, Inc. 786 Lucerne Drive Sunnyvale, CA 94085 Telephone: 408.738.9260 www.compbio.com Premier Preclinical Contract Research Organization Over 20 years of experience
More informationPharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal
Pharmacokinetics Processes, Mathematics, and Applications Second Edition Peter G. Welling Institut de Recherche Jouveinal ACS Professional Reference Book American Chemical Society Washington, DC Contents
More informationNon-clinical Assessment Requirements
Non-clinical Assessment Requirements Presented by: Maria Nieto-Gutierrez Safety and Efficacy of Medicines/Human Medicines Development and Evaluation An agency of the European Union Contents: Relevance
More informationGuideline on the non-clinical requirements for radiopharmaceuticals
1 2 3 15 November 2018 EMA/CHMP/SWP/686140/2018 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Draft Draft agreed by Safety Working Party October 2018 Adopted by CHMP for release for consultation
More informationGuidelines and criteria for seeking approval to conduct clinical trials in Ayurveda, Siddha and Unani system.
Guidelines and criteria for seeking approval to conduct clinical trials in Ayurveda, Siddha and Unani system. Application for seeking approval of the Central Government for conduct of clinical trial in
More information2017 PROGRAM Hands-On Training
- FORMAT - - REGISTRATION FEE - 2 days training From Thursday morning to Friday evening 590 euros* without VAT Lectures Thursday morning Laboratory practices Rest of the time Training certificate can be
More informationLAB EXPERTS AT YOUR SIDE Over twenty years of experience
LAB EXPERTS AT YOUR SIDE Over twenty years of experience About us SYNLAB Pharma offers a broad range of laboratory services to the biotechnology, pharmaceutical and cosmetic industries as well as to manufacturers
More informationGet ready for Meeting your information requirements. 11 th Stakeholder s Day. 25 May 2016
Get ready for 2018 Meeting your information requirements 11 th Stakeholder s Day 25 May 2016 Laurence Hoffstadt, PhD Senior Scientific Officer Evaluation Directorate Key messages It takes time Get organised
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationNewsletter. News from BSL BIOSERVICE. No. 2 - July 2014
Newsletter No. 2 - July 2014 News from BSL BIOSERVICE we are pleased to announce our next newsletter in a new dress. Our ambition is presenting our future news in a more friendly manner. Many things have
More informationRegulatory compliance in Non-Clinical development
Regulatory compliance in Non-Clinical development SME Workshop Presented by Milton Bonelli on 3 October 2016 Clinical Pharmacology and Non-Clinical Office - Human Medicines R & D Support Division An agency
More information**MATERIAL SAFETY DATA SHEET**
Date Issued: August 19, 2009 Version: 5.0 Supersedes: August 8, 2006 Page 1 of 5 Section 1 Product and Company Identification Product Name: Herceptin Chemical Name: Anti-p185 HER2 Chemical Family: High
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationMicrodose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry
Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationNational Health Surveillance System (SNVS)
November 19 th, 2014 The National Health Surveillance System National Health Surveillance System (SNVS) Integrates the Unified Health System (SUS) Integrated by the Federal, State and Local level Coordinated
More informationEARLY DRUG DEVELOPMENT
EARLY DRUG DEVELOPMENT Strategies and Routes to First-in-Human Trials Edited by MITCHELL N. CAYEN Cayen Pharmaceutical Consulting, LLC WILEY A JOHN WILEY & SONS, INC., PUBLICATION Contributors Foreword
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationAnnex 2: Registration Categories and Application Information Requirements of Chemical Drugs
Annex 2: Registration Categories and Application Information Requirements of Chemical Drugs I Registration Categories 1) New chemical entity never Launched in any country. i. Drug substance and its preparations
More informationInstitute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1
Institute of Pharmaceutical Technology and Biopharmacy University of Pécs 2017. szeptember 22. 1 Pre-discovery Goal: Understand the disease and choose a target molecule. How: Scientists in pharmaceutical
More informationDISCOVER OUR SEGMENT CHEMICALS/ REACH
DISCOVER OUR SEGMENT CHEMICALS/ REACH Our focus Dr Thomas Roth Head of Chemicals, Cosmetics, Consumer Products and Feed & Food Additives In SCC, you have found the perfect partner for your substance rollout
More informationNatural Products and Drug Discovery
Natural Products and Drug Discovery Secondary metabolism Building blocks & Phytochemicals Drug discovery 26-Oct-18 2 Secondary metabolism: Biochemical reactions derived from primary metabolic pathways
More informationJoint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products
Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Table of contents 1.Introduction...2 2.Scope...3 3.Discussion...4 3.1. Chemistry, manufacturing, and controls...4
More informationThe Long Range Science Strategy (LRSS) of Cosmetics Europe
The Long Range Science Strategy (LRSS) of Cosmetics Europe Repeated dose systemic toxicity 2016 Bas Blaauboer Aim of LRSS: Development of a strategy to determine safety of cosmetic ingredients and products
More information参考資料. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. Draft
参考資料 1 2 3 4 5 Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Draft 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Table of contents 1.
More informationHow do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug?
Pharmacokinetics : Basic Principles verview 1. PK : Basic principles and processes 2. Important PK Parameters 3. Modulating PK Parameters 4. PK : Drugs vs. contrast agents Twan Lammers Dept. of Experimental
More informationPreclinical safety testing of diagnostic and therapeutic radiopharmaceuticals - regulatory requirements
ESSR 14: 17th European Symposium on Radiopharmacy and Radiopharmaceuticals Pamplona, 25 April 2014 Preclinical safety testing of diagnostic and therapeutic radiopharmaceuticals - regulatory requirements
More informationInternational Council for Harmonisation (ICH) Safety Guideline Updates
International Council for Harmonisation (ICH) Safety Guideline Updates ICH Regional Public Meeting Canada-U.S. Regulatory Cooperation Council November 12, 2015 Alisa Vespa, Ph.D. Health Canada Active ICH
More informationREGULATORY ASSURANCE R&D SUPPORT
CHEMICALS & MATERIALS SCIENCES REGULATORY ASSURANCE R&D SUPPORT Helping you to achieve Total Quality Assurance INTERTEK REGULATORY ASSURANCE Chemicals and Materials Sciences Regulatory Assurance and R&D
More information